Japanese drugmaker Astellas reported it has begun Phase II trials of ASP0485 for prophylaxis of renal transplant rejection.
ASP0485 is a compound that inhibits T-cell costimulation by blocking interaction between antigen presenting cells and T-cells. The company will begin Phase II trials for this indication in North America and Europe.
Astellas said it expects ASP0485 to be used concomitantly with the company’s immunosuppressant Prograf.
ASP0485 is available commercially under the brand name Amevive for the treatment of psoriasis in 12 countries, including the U.S.